Urticarial Vasculitis After First Denosumab Injection in an Osteoporotic Woman Diagnosed with Cushing’s Syndrome

Abstract

Denosumab is a human-derived monoclonal immunoglobulin G2 antibody against the receptor activator of nuclear factor kappa B ligand, inhibiting the differentiation and function of osteoclast precursor cells by its antiosteoclastic action. Denosumab is approved for postmenopausal, glucocorti coid-induced, and male osteoporozis with high risk of fracture. The use of denosumab has increased in recent years. While new medications continue to be developed, the number of agents causing drug-induced vasculitis is expected to increase. It may be a good strategy to identify risk factors for vasculitis development and look for these factors before drug administration. Here, we present a rare complication of denosumab, urticarial vasculitis, after the first denosumab injection in an osteoporotic woman diagnosed with Cushing’s syndrome.

Cite this article as: İmre E, Şeker A, Gogas Yavuz D. Urticarial vasculitis after first denosumab injection in an osteoporotic woman diagnosed with Cushing’s syndrome. Turk J Endocrinol Metab. 2022;26(3):181-183.